ArticlePharmaceutical research2025
Development and Optimization of Myricetin Loaded Inhalable Microsphere to Treat COPD.
Article in Pharmaceutical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo develop and optimize myricetin-loaded inhalable microspheres using ionotropic gelation technique for sustained pulmonary delivery in Chronic Obstructive Pulmonary Disease (COPD) treatment.
methodsMyricetin-loaded microspheres were prepared using varying concentrations of gellan gum and sodium alginate through a 3
resultsThe optimized formulation (DF4) exhibited spherical morphology with ideal particle size for pulmonary delivery (7.72 μm), high entrapment efficiency (72.84%), and negative zeta potential ensuring colloidal stability. This formulation demonstrated excellent aerodynamic properties (FPF 31.71%), sustained drug release over 12 h, and remarkable stability over 6 months under both accelerated and real-time storage conditions. The formulation showed significant bronchodilatory activity with 63.47% relaxation at 25 μg/ml, achieving approximately 80.8% efficacy compared to theophylline anhydrous.
conclusionThe optimized myricetin-loaded inhalable microspheres represent a promising pulmonary delivery system for COPD management, offering advantages of sustained drug release, improved lung deposition, and significant bronchodilatory effect. This formulation holds potential for reducing dosing frequency, enhancing patient compliance, and improving therapeutic outcomes in COPD patients, warranting further in vivo studies before clinical translation.
Indexed as
Identifiers
41219567What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.